EWNYSEHealthcare

EDWARDS LIFESCIENCES CORP

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$102.14

+1.31%

Alpha Vantage · 11/6/2026

Industry: Medical DevicesCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze EW free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+21.3%

3 months

+11.0%

6 months

+27.7%

1 year

+23.9%

Year to date

+19.8%

52-week range

$75.87 – $102.14

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$58.73B

P/E

57.5

P/B

5.4

P/S

8.8

Revenue

$6.67B

Net income

$1.02B

Diluted EPS

1.77

Gross margin

78.00%

Net margin

15.30%

Return on equity

9.70%

Total debt

$704.5M

Cash

$3.11B

Free cash flow

$1.42B

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$1.72B	$307.5M	78.50%	17.90%	$506.7M
Jun 30, 2026	$1.74B	$241.9M	77.50%	13.90%	$585M
Mar 31, 2026	$1.65B	$380.7M	78.00%	23.10%	-$21.1M
Dec 31, 2025	$1.57B	$91.2M	78.10%	5.80%	$353.5M
Sep 30, 2025	$1.55B	$291.1M	77.80%	18.70%	$516.2M
Jun 30, 2025	$1.53B	$333.2M	77.50%	21.70%	$240.9M
Mar 31, 2025	$1.41B	$358M	78.70%	25.30%	$224.4M
Dec 31, 2024	$1.39B	$385.6M	78.90%	27.80%	-$177.3M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent EW news

All market news

JUVE Patent·Oct 28, 202651 signal

Edwards suffers setback at EPO in heart-valve dispute with Meril

Edwards Lifesciences has suffered a significant setback in its ongoing heart-valve dispute with Indian competitor Meril Life Sciences after the EPO's Board of Appeal revoked one of Edwards' key patents in full. This decision overturns a previous ruling by the Opposition Division and has direct consequences for parallel UPC proceedings, which are currently under appeal. The revocation of EP 4 151 181 removes the basis for an injunction previously granted against Meril at the UPC.

Original source